Ann: Ethics Application Submitted for Phase 1 Trial, page-7

Whilst there was a lot of frustration and disbelief at the time of the capital raising, I think in time it will be seen as the right and best thing the company could have done.

Sure it could have been done at a higher price, less dilution, although it is what it is.

Now that the company's capital position is secured and the next raising a long way off I am looking forward to seeing the company re-rate accordingly on Phase 1 commencement and IF it achieves safe Phase 1 results. I am confident they will (based on pre-clinical) results.

Big future ahead for this company and it is just the beginning.